Effect of B-cell mAbs on survival of tumor-bearing SCID mice. (A) SCID mice (10 per group) were injected intravenously with WSU-FSCCL (2.5 × 106 cells/mouse). mAbs were given twice weekly for 4 weeks starting 1 day after injection of cells. (B) SCID mice (6 per group) were injected intravenously with Namalwa (5 × 106 cells). Therapy began 1 day after injection of cells. Mice received 1.75 mg/kg (35 μg) subcutaneously of IMMU-114 3 times per week for 2 weeks. Other groups received 25 mg/kg (500 μg) intraperitoneal injections of veltuzumab, milatuzumab, or epratuzumab every 4 days for a total of 8 injections. (C) SCID mice (10 per group) were injected intravenously with Raji (2.5 × 106 cells/mouse). Therapy began 5 days after injection of cells. Mice received 1.75 mg/kg (35 μg) subcutaneously of veltuzumab or IMMU-114 3 times per week for 2 weeks.
